Rezolute, Inc. (RZLT)
NASDAQ: RZLT · IEX Real-Time Price · USD
3.430
+0.130 (3.94%)
At close: Apr 19, 2024, 4:00 PM
3.390
-0.040 (-1.17%)
After-hours: Apr 19, 2024, 7:58 PM EDT
Company Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States.
The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Nevan Charles Elam J.D. |
Contact Details
Address: 275 Shoreline Drive, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650-206-4507 |
| Website | rezolutebio.com |
Stock Details
| Ticker Symbol | RZLT |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001509261 |
| CUSIP Number | 76200L309 |
| ISIN Number | US76200L3096 |
| Employer ID | 27-3440894 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nevan Charles Elam J.D. | Founder, Chief Executive Officer and Acting Chairman of the Board |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer |
| Daron G. Evans M.B.A., M.S. | Chief Financial Officer |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific and Patient Affairs |
| Michael R. Deperro | Senior Vice President and Head of Corporate Development |
| Michael Covarrubias | Senior Vice President and Head of Program & Portfolio Management |
| Chris Milks | Vice President and Head of Finance |
| Dr. Raj Agrawal M.D. | Vice President and Head of Ophthalmological Clinical Development |
| Robyn Sweinhart | Vice President and Head of Quality |
| Erin O'Boyle | Senior Vice President and Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | 10-Q | Quarterly Report |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |